Impact of prior treatment and depth of response on survival in MM-003, a randomized phase 3 study comparing pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed/refractory multiple myeloma

Pomalidomide is a distinct oral IMiD(®) immunomodulatory agent with direct antimyeloma, stromal-support inhibitory, and immunomodulatory effects. The pivotal, multicenter, open-label, randomized phase 3 trial MM-003 compared pomalidomide + low-dose dexamethasone vs high-dose dexamethasone in 455 pat...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Haematologica
Main Authors: San Miguel, Jesus F., Weisel, Katja C., Song, Kevin W., Delforge, Michel, Karlin, Lionel, Goldschmidt, Hartmut, Moreau, Philippe, Banos, Anne, Oriol, Albert, Garderet, Laurent, Cavo, Michele, Ivanova, Valentina, Alegre, Adrian, Martinez-Lopez, Joaquin, Chen, Christine, Renner, Christoph, Bahlis, Nizar Jacques, Yu, Xin, Teasdale, Terri, Sternas, Lars, Jacques, Christian, Zaki, Mohamed H., Dimopoulos, Meletios A.
Formato: Artigo
Idioma:Inglês
Publicado em: Ferrata Storti Foundation 2015
Assuntos:
Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4591766/
https://ncbi.nlm.nih.gov/pubmed/26160879
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2015.125864
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados